Open AccessMR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction
Author(s) -
Bo Ram Kim,
Seung Hong Choi,
Tae Jin Yun,
Sang Kun Lee,
Shin Young Park,
Tae Min Kim,
Ji Hoon Kim,
Sun Won Park,
Chul Ho Sohn,
Shin Young Park,
Il Han Kim
Publication year - 2016
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0166096
Subject(s) - glioblastoma , temozolomide , medicine , chemoradiotherapy , tumor progression , progression free survival , concomitant , effective diffusion coefficient , nuclear medicine , magnetic resonance imaging , pathology , oncology , radiation therapy , radiology , overall survival , cancer , cancer research
Purpose To analyze the enhancement patterns and apparent diffusion coefficient (ADC) values of non-measurable surgical cavity wall enhancement pattern, newly appearing after completion of standard concurrent chemoradiotherapy (CCRT) with temozolomide in glioblastoma patients for the prognosis prediction. Materials and Methods From January 2010 to April 2014, among 190 patients with histopathologically confirmed glioblastoma, a total of 33 patients with non-measurable wall enhancement on post-CCRT MR imaging were enrolled and divided into two subgroups: non-progression (n = 18) and progression groups (n = 15). We analyzed the wall enhancement patterns, which were categorized into three patterns: thin, thick and nodular enhancement. ADC values were measured in the enhancing portions of the walls. The progression-free survival (PFS) related to the wall enhancement was analyzed by Kaplan-Meier analysis, and survival curves were compared using the log-rank test. Results Statistically significant differences in the surgical cavity wall enhancement patterns was shown between the progression and non-progression groups ( P = 0 . 0032 ). Thin wall enhancement was more frequently observed in the non-progression group, and thick or nodular wall enhancement were observed in the progression group ( P = 0 . 0016 ). There was no statistically significant difference in the mean ADC values between the progression and non-progression groups. The mean PFS was longer in patients with thin wall enhancement than in those with nodular or thick wall enhancement (35.5 months vs. 15.8 months, P = 0 . 008 ). Conclusion Pattern analysis of non-measurable surgical cavity wall enhancement on post-CCRT MR imaging might be useful tool for predicting prognosis of GBM patient before clear progression of non-measurable disease.